Ixazomib
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Ixazomib: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma
One-Sentence Summary
Ixazomib is an oral proteasome inhibitor originally used to treat plasma cell myeloma (multiple myeloma). The TxGNN model predicts it may be effective for indolent plasma cell myeloma. Currently there are 0 registered clinical trials and 3 publications (two real-world studies and one case report), none of which studies an indolent or smoldering population specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plasma cell myeloma (taken from the knowledge-graph indication data, as the Singapore licence records contain no indication text) |
| Predicted New Indication | Indolent plasma cell myeloma |
| TxGNN Prediction Score | 96.17% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the known drug class, ixazomib is an oral proteasome inhibitor that targets the beta-5 subunit of the 20S proteasome. Its efficacy in relapsed/refractory multiple myeloma is established through the TOURMALINE-MM1 phase 3 trial, in combination with lenalidomide and dexamethasone.
Indolent (smoldering) myeloma is an earlier-stage plasma cell neoplasm. It is biologically related to multiple myeloma and relies on the same proteasome-mediated protein homeostasis pathway, so the mechanistic rationale is plausible.
However, the link is indirect. The available literature studies relapsed/refractory multiple myeloma, not indolent or smoldering disease. This mechanistic reasoning relies on class knowledge, not on supplied mechanism data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38558233 | 2024 | Cohort | Cancer Medicine | Real-world retrospective-prospective analysis of ixazomib, lenalidomide and dexamethasone (IRd) in relapsed/refractory multiple myeloma in northern Italy |
| 32193630 | 2020 | Registry study (classified as Review) | Annals of Hematology | Multi-site Israeli registry assessing whether real-world outcomes of ixazomib-based regimens match the TOURMALINE-MM1 trial |
| 42719364 | 2026 | Case report | Therapeutic Advances in Hematology | Fulminant extramedullary relapse of multiple myeloma with cardiac, vascular and multivisceral involvement |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15163P | NINLARO CAPSULE 3mg | Capsule | Not stated in the licence record |
| SIN15162P | NINLARO CAPSULE 2.3mg | Capsule | Not stated in the licence record |
| SIN15164P | NINLARO CAPSULE 4mg | Capsule | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (proteasome inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; blood counts and liver and renal function are generally monitored with antineoplastic therapy |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs in total; 20 are listed in the data compiled for this report. Most are of Moderate severity. The Major interactions listed are:
- Deferiprone
- Samarium (153Sm) lexidronam
- Lumacaftor
Examples of Moderate interactions include metronidazole, simvastatin, rosuvastatin, naltrexone, chloroquine, hydroxychloroquine and disulfiram.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high (96.17%), and the mechanism is plausible given ixazomib's established role in multiple myeloma. However, no trials are registered, and the supplied literature does not study indolent or smoldering myeloma. Package insert safety information is also missing, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Mechanism of action data from DrugBank
- Searches for clinical studies, and any registered trials, of ixazomib in smoldering or indolent myeloma
- A review of the Major drug interactions, including those with deferiprone, samarium lexidronam and lumacaftor
- Confirmation of the approved indication wording on the Singapore licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.